Understanding how PIM2 helps multiple myeloma cells survive
Novel pro-survival mechanisms of PIM2 in multiple myeloma
This study is looking at a protein called PIM2 that might help multiple myeloma cells survive treatment, and by understanding how it works, researchers hope to find new ways to make treatments more effective for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11056768 on NIH RePORTER |
What this research studies
This research investigates the role of PIM2, a protein that may help multiple myeloma cells resist treatment. By examining how PIM2 is regulated and its effects on cancer cell survival, the study aims to identify new therapeutic targets that could improve treatment outcomes. The researchers will use advanced techniques to analyze the expression and activity of PIM2 in multiple myeloma cells, particularly focusing on a novel inhibitor that selectively targets PIM2. This approach could lead to more effective treatments for patients with this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma who are seeking new treatment options.
Not a fit: Patients with other types of cancers or those who do not have multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve survival rates and treatment responses for patients with multiple myeloma.
How similar studies have performed: Previous research has shown promise in targeting PIM kinases for cancer treatment, suggesting that this approach could be a meaningful advancement in the field.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Lee, Kelvin P. — Indiana University Indianapolis
- Study coordinator: Lee, Kelvin P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.